Effect of clinical pharmaceutical care on rational use of nirmatrelvir/ritonavir tablets
Objective To explore the influence of clinical pharmaceutical care on the rational initial use of nirmatrelvir/ritonavir tablets,providing a reference for the clinical pharmaceutical care model of new drugs.Methods A retrospective anal-ysis was conducted on the medical records of inpatients treated with nirmatrelvir/ritonavir tablets at the China-Japan Friendship Hospital from December 10,2022,to January 10,2023.According to the time of drug use,patients who used the drug from December 10 to 20,2022 were included in the initial intervention group for the initial implementation of clinical pharmacy ser-vices,including pre-audit maintenance,medication guidance,and consultation of complex cases.Patients who used this drug from December 21 to 31 were included in the mid-intervention group,representing the stage of gradual optimization of clinical pharmaceutical care.Patients who used this drug from January 1 to 10,2023 were included in the late-intervention group,representing the stage after optimizing clinical pharmacy services,with strengthened pre-review and key education.The proportions of inappropriate combined medication use and inappropriate dosage for patients with liver or kidney damage were compared among the groups.Results A total of 452 patients were included,including 54 cases in the initial intervention group,353 cases in the mid-intervention group,and 45 cases in the late-intervention group.Compared with the initial inter-vention group,the proportion of inappropriate combinations of drugs and inappropriate dosages for patients with kidney injury in the mid-intervention group and the late-intervention group were lower(51.9%vs 33.4%and 24.4%,59.3%vs 29.7%and 17.8%),and the late-intervention group was lower than the mid-intervention group,the differences were statistically sig-nificant(P<0.05).The proportions of inappropriate dosages for patients with liver damage showed no significant difference among the groups(P>0.05).A total of 79 consultations were conducted,and 72 sessions(91.1%)were adopted by physi-cians.Conclusion Clinical pharmaceutical services have played a positive role in promoting the rational use of nirmatrelvir/ritonavir tablets and reducing clinical medication issues.
pharmaceutical carenirmatrelvirritonavirCOVID-19rational drug use
NETL
NSTL
万方数据
